Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
Find more results for teva
-0.68 (-1.86%)
After Hours: 35.98 +0.01 (0.03%)
Feb 22, 5:05PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 35.96 - 36.69
52 week 31.90 - 59.35
Open 36.50
Vol / Avg. 6.92M/14.23M
Mkt cap 38.43B
P/E 232.18
Div/yield 0.34/3.78
EPS 0.15
Shares 1.02B
Beta 0.58
Inst. own 62%
Feb 9, 2017
Q4 2016 Teva Pharmaceutical Industries Ltd Earnings Release (Estimated)
Dec 8, 2016
Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -14.96% 1.38%
Operating margin -2.11% 9.83%
EBITD margin - 25.77%
Return on average assets -4.06% 0.41%
Return on average equity -12.84% 0.22%
Employees 42,888 -
CDP Score - 96 B


5 Basel St., P.O. Box 3190
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson's disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Officers and directors

Yitzhak Peterburg Interim President and Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Eyal Desheh Group Executive Vice President, Chief Financial Officer
Age: 63
Bio & Compensation  - Reuters
Dipankar Bhattacharjee President and Chief Executive Officer - Global Generic Medicines Group
Age: 55
Bio & Compensation  - Reuters
Carlo De Notaristefani President and Chief Executive Officer, Global Operations
Age: 58
Bio & Compensation  - Reuters
Robert Koremans President, Chief Executive Officer - Global Specialty Medicines
Age: 54
Bio & Compensation  - Reuters
Iris Beck-Codner Group Executive Vice President - Corporate Marketing Excellence and Communication
Age: 50
Bio & Compensation  - Reuters
Mark Sabag Group Executive Vice President, Human Resources
Age: 45
Bio & Compensation  - Reuters
Timothy R. Wright Executive Vice President, Business Development, Strategy and Commercial Innovation
Age: 58
Bio & Compensation  - Reuters
Michael R. Hayden President - Global Research and Development, Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
David Stark Chief Legal Officer
Bio & Compensation  - Reuters